Your Cart

IBX Secures Additional Capital — Shareholders Exercise Options

IBX Secures Additional Capital — Shareholders Exercise Options

Imagion Biosystems announce that it has received a total of $82,939.98 for the exercise of Listed Options.

Comprised of $64,189.98 for 2,139,666 Listed Options exercisable at 3 cents and expiring on 28 April 2023 and $18,750 for the exercise of 375,000 Listed Options exercisable at 5 cents and expiring on 26 November 2021.

The exercise of these options has resulted in the issue of 2,514,666 fully paid ordinary shares, as outlined in the attached application for quotation (Appendix 2A).

Read Appendix 2A.

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.